Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

TNB-738

Alternative Names: tnb-738, tnb 738, tnb738
Latest Update: 2024-03-20
Latest Update Note: Clinical Trial Update

Product Description

TNB-738 is a fully human bispecific antibody used to inhibit human CD38 enzyme. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05215912)

Mechanisms of Action: CD38 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TeneoFour
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TNB-738

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Inflammation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TNB-738

P1

Completed

Inflammation

2023-05-04

28%

Recent News Events

Date

Type

Title

08/28/2022

PubMed

 Targeting CD38 in Neoplasms and Non-Cancer Diseases.

10/27/2021

News Article

 Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions